跳至主要内容
临床试验/JPRN-jRCT2051200104
JPRN-jRCT2051200104已完成1 期

A Phase 1 Study of KK6483 in Healthy Male Volunteers

Yagi Michio0 个研究点目标入组 40 人开始时间: 2020年12月24日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 45age old(—)
性别
Male

入选标准

  • 1) Those who have provided voluntary written consent to participate in the study
  • 2) Men aged >= 20 to < 45 years at the time of informed consent.
  • 3) Those with BMI >= 18.5 to < 25.0 at the time of preliminary test

排除标准

  • 1) Those with present illness requiring treatment
  • 2) Those with a history of or current drug allergy
  • 3) Those currently having respiratory disease, heart disease, gastrointestinal disease, renal disease, or hepatic disease
  • 4) Those with a history of or current psychiatric disease
  • 5) Those currently having clinically significant orthostatic hypotension
  • 6) Those who have had a bacterial, viral, fungal, or parasitic infection within 28 days prior to signing the informed consent

研究者

发起方
Yagi Michio

相似试验

进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864Renal cell carcinoma
EUCTR2020-002075-35-ATMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864Renal cell carcinoma
EUCTR2020-002075-35-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)Renal cell carcinomaMedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864
EUCTR2020-002075-35-GRMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)
EUCTR2020-002075-35-BEMerck Sharp & Dohme LLC708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864Renal cell carcinoma
EUCTR2020-002075-35-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.708